Open AccessA framework for decision making of migraine treatment with anti- CGRP monoclonal antibodies: a guide for real-world practice and public policies
Author(s) -
Reinilza Nunes da Gama,
Thaiza Agostini Córdoba de Lima,
Iron Dangoni Filho,
Mário Fernando Prieto Peres
Publication year - 2020
Language(s) - English
Resource type - Journals
ISSN - 2763-6178
DOI - 10.48208/headachemed.2020.20
Subject(s) - migraine , monoclonal antibody , calcitonin gene related peptide , medicine , chronic migraine , developing country , monoclonal , intensive care medicine , antibody , immunology , receptor , neuropeptide , economics , economic growth
Anti-CGRP monoclonal antibodies have been developed for migraine preventive treatment. There is evidence of good efficacy and safety of these medications; however, cost is a factor that interferes with the choice of treatment. This paper proposes a framework in order to better assist the decision-making processes on the use of these drugs in developing countries without coverage of health care costs for migraine. The framework was built after reviewing phase II and III studies on episodic and chronic migraine treatment with erenumab, galcanezumab and fremanezumab.